Clarity Pharmaceuticals (ASX:CU6) Total Liabilities: A$22.86 Mil (As of Dec. 2025)


ASX:CU6 Clarity Pharmaceuticals Ltd ASX:CU6
39 GF Score
Price A$2.10
! 2 Warning Signs
View Full Analysis

What is Clarity Pharmaceuticals Total Liabilities?

Clarity Pharmaceuticals ASX:CU6 +15.70% 39 Total Liabilities is A$22.86 Mil as of Dec. 2025. GuruFocus rates ASX:CU6 with a GF Score™ of 39/100. The stock has 2 warning signs investors should review.

Clarity Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2025 was A$22.86 Mil.

Clarity Pharmaceuticals's quarterly Total Liabilities increased from Dec. 2024 (A$9.71 Mil) to Jun. 2025 (A$10.94 Mil) and increased from Jun. 2025 (A$10.94 Mil) to Dec. 2025 (A$22.86 Mil).

Clarity Pharmaceuticals's annual Total Liabilities increased from Jun. 2023 (A$7.72 Mil) to Jun. 2024 (A$8.33 Mil) and increased from Jun. 2024 (A$8.33 Mil) to Jun. 2025 (A$10.94 Mil).

Clarity Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for Clarity Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clarity Pharmaceuticals Total Liabilities Chart

Clarity Pharmaceuticals Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Total Liabilities
7.59 7.72 8.33 10.94

Clarity Pharmaceuticals Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.11 8.33 9.71 10.94 22.86
ASX:CU6
39GF Score
Clarity Pharmaceuticals Ltd ASX:CU6
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clarity Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Clarity Pharmaceuticals's Total Liabilities for the fiscal year that ended in Jun. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=10.38+(0+-0.0010000000000001
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.562+0)
=10.94

Total Liabilities=Total Assets (A: Jun. 2025 )-Total Equity (A: Jun. 2025 )
=101.172-90.231
=10.94

Clarity Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=22.308+(0+0.547
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=22.86

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=255.67-232.814
=22.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of A$22.86 Mil mean?
Clarity Pharmaceuticals (ASX:CU6) has a Total Liabilities of A$22.86 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Clarity Pharmaceuticals and its competitors.
Is Clarity Pharmaceuticals' Total Liabilities too high?
Clarity Pharmaceuticals' current Total Liabilities is A$22.86 Mil. Overall, Clarity Pharmaceuticals has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Clarity Pharmaceuticals' Total Liabilities compare to VRTX and REGN?
Clarity Pharmaceuticals' Total Liabilities of A$22.86 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Clarity Pharmaceuticals and its competitors. Clarity Pharmaceuticals's current Total Liabilities is A$22.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clarity Pharmaceuticals stock overvalued right now?
Clarity Pharmaceuticals (ASX:CU6) has a current Total Liabilities of A$22.86 Mil. The current Total Liabilities is A$22.86 Mil. Clarity Pharmaceuticals' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Clarity Pharmaceuticals (ASX:CU6), the current Total Liabilities is A$22.86 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Clarity Pharmaceuticals Business Description

Other Exchanges CLRPF:USA1F4:Germany
Address 2-4 Cornwallis Street, Suite 212a, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, using its SAR Technology platform. Clarity's Targeted Copper Theranostic (TCT) platform of products utilize pairing of copper isotopes, specifically copper-64 (Cu-64 or 64Cu) for imaging and copper-67 Cu-67 or 67Cu) for therapy, which delivers accuracy and precision in the treatment of a range of cancers. The company's clinical development pipeline includes SAR-bisPSMA, SAR-Bombesin, and Sartate, in their different stages of development for the diagnosis and/or treatment of various cancers. Clarity operates in a single segment, which is the development of radiopharmaceuticals. Geographically, it operates in Australia and the United States.
39GF Score

Get the complete analysis for ASX:CU6

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.10
Price